ArticleCrohn's & colitis 3602026
FUT2 non-secretor status is not associated with disease phenotype or outcomes in patients with Crohn's disease.
Article in Crohn's & colitis 360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The fucosyltransferase 2 gene (FUT2) is responsible for the regulation of mucosal blood type antigens which can act as receptors for bacterial adhesion and regulate intestinal flora. A homozygous nonsense mutation in this gene leads to the absence of these antigens, termed FUT2 non-secretor status, and is associated with the development of Crohn's disease (CD). The mechanism of this association is likely via changes in homeostatic symbiosis, thus promoting development of inflammation. However, the impact of FUT2 genotype on CD phenotype and outcomes is not known. Methods: Subjects were prospectively enrolled into a single-center translational IBD registry. All patients with CD who had available DNA extracted from peripheral blood for genotyping were included. Genotyping was performed using the rs601338-AA SNP, which represents the nonsense mutation (428GA) shown to be causing non-secretor status. Baseline demographics, disease phenotype, CD-related surgeries, and hospitalizations were also assessed retrospectively and statistically compared based on FUT2 genotype. Results: 635 patients with CD were included in the analysis, including 178 FUT2 wild-type (WT), 314 heterozygous (HET) and 143 homozygous (O) patients. The mean duration of follow-up was 8 years and 2 months. There were no statistically significant differences detected between genotypes when comparing sex, race, smoking status, body-mass index, and age of onset. Presence of extra-intestinal manifestations including arthritis, uveitis, erythema nodosum, pyoderma gangrenosum and primary sclerosing cholangitis, as well as disease location and behavior were also found to be similar when compared between O and WT, O and HET, and O and HET plus WT populations. The mean number of biologics used between groups was 1.50 (O), 1.39 (HET)and 1.42 (WT) ( Conclusion: In this single-center analysis of 635 patients with CD, the FUT2 genotype was not associated with disease phenotype, disease severity, or clinical outcomes. These data suggest that while lack of fucosylation is associated with developing CD, it does not play a major role in driving disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.